Table 4.

Features associated with progression from oligoarthritis to polyarthritis based on 136 patients (excluding dactylitis, enthesitis, and axial disease)a.

CovariateUnivariate AnalysisMultivariate Analysis
Full ModelReduced Model
HR (95% CI)PHR (95% CI)PHR (95% CI)P
Age, yrs1.00 (0.98–1.04)0.571.01 (0.99–1.04)0.30
PsA duration, yrs0.99 (0.88–1.12)0.890.97 (0.86–1.09)0.61
Sex (M vs F)0.84 (0.43–1.62)0.600.87 (0.47–1.61)0.66
LE SJ1.18 (0.51–2.72)0.701.04 (0.44–2.48)0.93
UE SJ1.97 (1.04–3.72)0.041.99 (1.03–3.84)0.052.01 (1.08–3.77)0.03
LE LJ0.58 (0.80–3.12)0.191.64 (0.77–3.54)0.20
UE LJ1.36 (0.59–3.12)0.471.27 (0.55–2.94)0.58
HAQ2.42 (1.26–4.67)0.0081.27 (0.49–3.31)0.64
SF-36 PCS0.96 (0.93–0.99)0.0080.98 (0.94–1.01)0.190.96 (0.94–0.99)0.006
SF-36 MCS0.97 (0.94–0.99)0.020.98 (0.95–1.01)0.16
PASI1.02 (0.98–1.06)0.431.01 (0.97–1.05)0.68
Elevated APR1.04 (0.58–1.87)0.900.92 (0.48–1.74)0.80
Highest medication
      NSAIDs0.64 (0.28–1.45)0.280.77 (0.32–1.87)0.56
      DMARDs1.51 (0.68–3.36)0.311.82 (0.77–4.32)0.18
      Biologics0.96 (0.34–2.69)0.931.14 (0.38–3.43)0.81
  • aBased on 136 patients with only the covariate information available at each clinic visit (46 progressed to polyarthritis). APR: acute-phase reactant; DMARD: disease-modifying antirheumatic drug; HAQ-DI: Health Assessment Questionnaire-Disability Index; LE: lower extremity; LJ: large joint; MCS: mental component summary score; NSAID: nonsteroidal antiinflammatory drugs; PASI: Psoriasis Area Severity Index; PCS: physical component summary score; PsA: psoriatic arthritis; SF-36: 36-item Short Form Health Survey; SJ: small joint; UE: upper extremity.